$SCNIOct 13, 2026, 7:51 AM ETAI processed6-K
Scinai signs $5.1M committed CDMO deal; committed orders rise to ~$7.6M
AI Summary
SCNI filed SEC Form 6-K. Scinai's subsidiary entered a definitive CDMO agreement with a U.S. Nasdaq-listed biopharma company that includes approximately $5.1 million in committed base service fees for CMC development and clinical manufacturing, expected to contribute revenue in 2026–2027 and support manufacturing planned to begin January 2027. Committed Customer Orders across Scinai’s Jerusalem and Yavne operations increased to roughly $7.6 million (≈300% from $1.9M at year-end 2025), and there is an indicative, uncommitted potential of about $5.85 million for additional clinical manufacturing in late 2027–H1 2028, excluding scale-up and other project costs.
Positives
- $5.1M of committed base service fees for development and clinical manufacturing expected to drive revenue in 2026–2027
- Committed Customer Orders increased to approximately $7.6M, up ~300% from $1.9M at year-end 2025
- Advance and milestone payments are expected to support cash flow and working capital during project execution
Negatives
- The $5.1M commitment is subject to contract performance and termination rights and therefore not guaranteed revenue
- The ~$5.85M additional clinical manufacturing value is indicative and uncommitted, subject to final scope, pricing and written authorization
- Potential revenues exclude pass-through purchases, scale-up, suite qualification and first-batch pricing, and recognized revenue may differ from customer billings